Prevalence of anxiety and depression among Chinese medical students over the past decade: A systematic review and meta-analysis.

Psychiatry ResMay 14, 2026 (epub)
Clinical ResearchPsychiatry

Jinping Wang, Hui Shu, Ziqi Zhou et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the prevalence of anxiety and depression among Chinese medical students over the past decade. The study found a pooled prevalence of 25.36% for anxiety and 31.75% for depression. Various factors, including gender and academic performance, were associated with these mental health conditions.

Key findings

  • The pooled prevalence of anxiety among Chinese medical students was 25.36%.
  • The pooled prevalence of depression among Chinese medical students was 31.75%.
  • Depression prevalence correlated with gender, race, residence, grades, exercise frequency, and family relationships.
  • Anxiety prevalence was related to gender and academic grades.

Why it matters

Understanding the prevalence of anxiety and depression in medical students is crucial for developing targeted mental health interventions, which can enhance student well-being and academic performance.

Source

PubMed · PMID 42142498

Published in Psychiatry Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.